Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer
dc.contributor.author | Goksel, G | |
dc.contributor.author | Taneli, F | |
dc.contributor.author | Uslu, R | |
dc.contributor.author | Ulman, C | |
dc.contributor.author | Dinc, G | |
dc.contributor.author | Coskun, T | |
dc.contributor.author | Kandiloglu, AR | |
dc.date.accessioned | 2025-04-10T10:34:40Z | |
dc.date.available | 2025-04-10T10:34:40Z | |
dc.description.abstract | This study was conducted to investigate the serum levels of her-2/neu and survivin in patients with early-stage breast cancer and their relationship with known histological parameters. Forty-one patients with early-stage breast cancer were investigated. Serum samples were collected from patients on their first admission before adjuvant chemotherapy, and from healthy controls. Serum her-2/neu and survivin levels were determined using an enzyme-linked immunosorbent assay. There was no difference in the levels of serum her-2/neu and survivin between the breast cancer patients and the control group. Serum her-2/neu concentration showed moderate correlations with disease stage and the Ki-67 level, and the serum survivin level showed a moderate correlation with progesterone receptor concentration. Serum levels of her-2/neu and survivin were not significantly related to age and histological parameters in patients with early-stage breast cancer. However, much research continues on the prognostic value of serum her-2/neu and survivin levels, and important new knowledge may ultimately emerge. | |
dc.identifier.issn | 0300-0605 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14701/40798 | |
dc.language.iso | English | |
dc.title | Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer | |
dc.type | Article |